Reducing mortality in newly diagnosed standard-risk acute promyelocytic leukemia in elderly patients treated with arsenic trioxide requires major reduction of chemotherapy: a report by the French Belgian Swiss APL group (APL 2006 trial).

ABSTRACT:

SUBMITTER: Rahme R 

PROVIDER: S-EPMC6278967 | biostudies-literature | 2018 Nov

REPOSITORIES: biostudies-literature